Related Experiment Videos
Clinical observations in children after prenatal benzodiazepine exposure
1Department of Pediatrics II, East Hospital, Gothenburg University, Sweden.
Insights
Prenatal exposure to benzodiazepines (BZD) is linked to birth defects and developmental issues in children. This study found a significant association between maternal BZD use and congenital malformations in newborns.
Area of Science:
- Perinatal Medicine
- Developmental Toxicology
- Clinical Teratology
Background:
- Benzodiazepine (BZD) use during pregnancy is a concern due to potential adverse effects on fetal development.
- Congenital malformations and neurodevelopmental deficits have been anecdotally linked to in utero BZD exposure.
- Objective assessment of this association requires controlled studies with reliable exposure markers.
Purpose of the Study:
- To investigate the association between prenatal benzodiazepine (BZD) exposure and specific congenital malformations.
- To determine if maternal serum BZD levels in early pregnancy correlate with observed neonatal outcomes.
- To establish a quantifiable link between BZD exposure and characteristic dysmorphic features and developmental issues.
Main Methods:
- Case-control study design comparing infants with specific congenital malformations to a control group.
- Analysis of maternal serum samples from early pregnancy for the presence of BZD and its metabolites.
- Clinical assessment of children for dysmorphic features, congenital anomalies, and neurodevelopmental status.
Main Results:
- Eight children with excessive in utero BZD exposure exhibited similar dysmorphic features, including kidney aplasia and cleft palate.
- Maternal serum BZD positivity was confirmed in 3 mothers, with 5 admitting regular BZD use.
- A statistically significant association (p = 0.00006) was found between BZD-positive serum tests and specific congenital malformations.
Conclusions:
- In utero benzodiazepine (BZD) exposure is significantly associated with a distinct pattern of congenital malformations.
- Maternal serum BZD testing in early pregnancy can identify exposure and predict adverse neonatal outcomes.
- These findings highlight the teratogenic potential of BZD and the need for caution during pregnancy.
Abstract:
Eight children excessively exposed to benzodiazepines (BZD) in utero are described. Five of the 8 mothers admitted regular use of BZD and in 3 mothers, stored serum from early pregnancy could be analysed and found positive for BZD and its metabolite. All the children had similar dysmorphic features, in addition, 1 child had aplasia of one kidney and 2 had cleft palate. At follow-up 2 children had become microcephalic. 2 were severely mentally retarded, 5 had a mild mental retardation and only 1 was of normal intelligence. In a case-control study, 4 neonatal diagnoses of congenital malformations, in our experience characteristic of fetal BZD exposure, were chosen as inclusion criteria. In 8 of 18 cases, blood samples from early pregnancy were positive for BZD as compared to 2 of 60 control samples. An association between BZD-positive serum tests and the particular diagnoses could be demonstrated (p = 0.00006).